( eved to be induced not only by the wide...)Trexima (Sumatriptan/Naproxen Sodium) Provided Relief of Both,Traditional and Non-traditional Migraine Symptoms,Health

eved to be induced not only by the widening of the blood vessels, or vasodilation, but also involves neurochemical release and prostaglandin production. These mechanisms lead to inflammation, resulting in increased pain perception and sensitization of nerves. Understanding the multiple mechanisms of migraine may also explain why migraine sufferers often experience a variety of non-traditional migraine symptoms in addition to head pain, nausea or vomiting, and sensitivity to light and sound. Stimulation of the main sensory nerve may cause referral of pain to any of the nerve's three branches, resulting in sinus or facial pain; it may also cause referral of pain to the sensory nerves of the posterior head and neck, resulting in neck pain.

Relief from Non-Traditional and Traditional Migraine Symptoms

The data are from two identical multi-center, double-blind, placebo- controlled cross-over studies of adult migraine sufferers. The study incorporated an early intervention model, in which patients were instructed to treat while migraine pain was mild and within one hour of onset. Endpoints included post-treatment incidence of traditional symptoms, defined as nausea, vomiting, photophobia (sensitivity to light) and phonophobia (sensitivity to noise); and non-traditional symptoms, defined as sinus pain/pressure and neck pain/discomfort. Response to these symptoms was measured at two and four hours. This is the first study to evaluate traditional and non-traditional migraine-associated symptoms in a controlled early intervention setting across multiple attacks.

In both studies, patients taking Trexima reported a significantly lower incidence of traditional and non-traditional migraine-associated symptoms compared to placebo at two and at four hours.

    -- The approximate difference between Trexima and placebo at two hours for

       each symptom was as follows: nausea (6 percent), sensitivity to light

       (22 percent), sensitivity to soun
'"/>




Page: 1 2 3 4 5 
Related medicine technology :

1. Trexima (Sumatriptan/Naproxen Sodium) Demonstrated Migraine-Free
Response Across Multiple Attacks
2. Trexima (Sumatriptan/Naproxen Sodium) Demonstrated Efficacy Across
Multiple Migraine Attacks
3. Trexima (Sumatriptan/Naproxen Sodium) Superior Efficacy Data
Published in JAMA
4. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for
Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical
Study
5. Late Breaking Data Released at ADA Showed that the Investigational
Use of Januvia and Metformin as Initial Combination Therapy
Provided Significant Glucose Lowering Efficacy over 54 Weeks in
Patients with Type 2 Diabetes
6. Novavax Pandemic Flu Vaccine Provided Protection Against a Lethal
Challenge of Live Virus, Pre-Clinical Data Show
7. Copaxone Treatment over Two Years after Short Term Induction with
Mitoxantrone Provided Sustained Benefits to Active
Relapsing-Remitting Multiple Sclerosis Patients
8. Daytrana (methylphenidate transdermal system) Provides Significant
Effectiveness in ADHD Symptom Relief in Both Boys and Girls
9. New Study Demonstrates that Lubiprostone May Improve Symptom Relief
Rates in Adults with Irritable Bowel Syndrome with Constipation
(IBS-C)
10. New Phase IV Clinical Study Indicates LidoSite Provides
Rheumatology Patients Superior Pain Relief
11. Frova Phase III Study Data Demonstrates That Short-Term Prevention
Treatment Reduces Frequency and Severity of Menstrual Migraine